Abstract:Background: Clinical, histopathological, and imaging variables have been associated with prognosis in patients with glioblastoma (GBM). We aimed to develop a multiparametric radiogenomic model incorporating MRI texture features, demographic data, and histopathological tumor biomarkers to predict prognosis in patients with GBM. Methods: In this retrospective study, patients were included if they had confirmed diagnosis of GBM with histopathological biomarkers and pre-operative MRI. Tumor segmentation was performed, and texture features were extracted to develop a predictive radiomic model of survival (<18 months vs. ≥18 months) using multivariate analysis and Least Absolute Shrinkage and Selection Operator (LASSO) regularization to reduce the risk of overfitting. This radiomic model in combination with clinical and histopathological data was inserted into a backward stepwise logistic regression model to assess survival. The diagnostic performance of this model was reported for the training and external validation sets. Results: A total of 116 patients were included for model development and 40 patients for external testing validation. The diagnostic performance (AUC/sensitivity/specificity) of the radiomic model generated from seven texture features in determination of ≥18 months survival was 0.71/69.0/70.3. Three variables remained as independent predictors of survival, including radiomics (p = 0.004), age (p = 0.039), and MGMT status (p = 0.025). This model yielded diagnostic performance (AUC/sensitivity/specificity) of 0.77/81.0/66.0 (training) and 0.89/100/78.6 (testing) in determination of survival ≥ 18 months. Conclusions: Results show that our radiogenomic model generated from radiomic features at baseline MRI, age, and MGMT status can predict survival ≥ 18 months in patients with GBM.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a multi - parameter radiogenomics model to predict the survival time of glioblastoma (GBM) patients. Specifically, the research aims to predict the prognosis of patients by combining baseline MRI images, histopathological biomarkers and demographic data. The research team hopes that through this model, GBM patients whose survival time may reach or exceed 18 months can be more accurately identified. ### Research Background Glioblastoma (GBM) is a highly malignant brain tumor. Despite progress in tumor detection and treatment, the prognosis of patients is still very poor. The standard treatment methods for GBM include maximum surgical resection, radiotherapy and chemotherapy, but the median survival time is only 14 months, the 1 - year survival rate is about 43%, and the 5 - year survival rate is only about 5%. Therefore, the development of effective prognostic prediction models is of great significance for improving patient management and treatment strategies. ### Research Methods 1. **Data Collection**: - A retrospective study was conducted on the data of 226 GBM patients. Finally, 116 patients were included for model development and 40 patients for external validation. - Patients must meet the following conditions: diagnosed as IDH wild - type GBM, received standardized treatment (radiotherapy and temozolomide chemotherapy), had preoperative MRI (including T1 - enhanced, FLAIR and diffusion sequences), and had available histopathological biomarkers (IDH - 1, EGFR, MGMT and ATRX) and survival data. 2. **Image Analysis**: - The MRI images were analyzed using FDA - approved software, and 368 radiomics features were extracted, including first - order and second - order texture features. - Manual segmentation was performed on the FLAIR, T1 - enhanced and diffusion images of each patient, and a volume of interest (VOI) containing the entire FLAIR high - signal area was generated. 3. **Statistical Analysis**: - One - way analysis of variance (ANOVA) was used to screen out radiomics features related to survival time. - The LASSO regularization method was applied to reduce the risk of overfitting, and independent predictors were determined by step - by - step logistic regression analysis. - Finally, a multi - parameter model combining age, MGMT status and radiomics features was constructed and tested in an external validation cohort. ### Main Results - **Radiomics Model**: - Seven significant features were screened out from 368 radiomics features. The diagnostic performance (AUC/sensitivity/specificity) of the radiomics model composed of these features in predicting survival time ≥ 18 months was 0.71/69.0/70.3. - **Multi - parameter Model**: - The diagnostic performance of the multi - parameter model combining age, MGMT status and radiomics features was 0.77/81.0/66.0 in the training set and 0.89/100/78.6 in the external validation set. - **Independent Predictors**: - Age (p = 0.039), MGMT methylation status (p = 0.025) and radiomics features (p = 0.004) were determined as independent predictors of survival time ≥ 18 months. ### Discussion - **Age**: - Younger patients have a better prognosis, which is consistent with previous research results. - Patients aged ≤ 59 years are significantly associated with a longer overall survival time. - **MGMT Methylation**: - The MGMT methylation status is an important prognostic indicator and is significantly associated with survival time ≥ 18 months. - The synergistic effect of age and MGMT methylation status further improves the prediction performance of the model. - **Radiomics Features**: - Radiomics features show good performance in predicting the survival time of GBM patients, especially when combined with clinical and histopathological data. ### Conclusion The research results show that a multi - parameter radiogenomics model combining baseline MRI images, age and MGMT methylation status can effectively predict the survival time ≥ 18 months of IDH wild - type GBM patients. The performance of this model in the training set and the external validation set shows high accuracy, providing a powerful tool for the prognosis assessment of GBM patients in clinical practice.

Multiparametric Radiogenomic Model to Predict Survival in Patients with Glioblastoma

Multiple Survival Outcome Prediction of Glioblastoma Patients Based on Multiparametric MRI

Reproducible and Interpretable Machine Learning-Based Radiomic Analysis for Overall Survival Prediction in Glioblastoma Multiforme

Integrated MRI radiomics, tumor microenvironment, and clinical risk factors for improving survival prediction in patients with glioblastomas

Radiomics-Based Machine Learning with Natural Gradient Boosting for Continuous Survival Prediction in Glioblastoma

Radiomics for Survival Analysis and Prediction in Glioblastoma (GBM)—A Preliminary Study

P13.14.A PREDICTION OF OVERALL SURVIVAL IN HIGH-GRADE GLIOMA USING MULTIPARAMETRIC MRI-BASED RADIOMICS. APPLICATION TO A MULTICENTER COHORT

A Multiparameter Radiomic Model for Accurate Prognostic Prediction of Glioma

Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma

Development and Validation of a MRI-Based Radiomics Prognostic Classifier in Patients with Primary Glioblastoma Multiforme.

Non-Invasive Prediction of Survival Time of Midline Glioma Patients Using Machine Learning on Multiparametric MRI Radiomics Features

Multi-parameter MRI Based Radiomics Nomogram for Predicting Telomerase Reverse Transcriptase Promoter Mutation and Prognosis in Glioblastoma.

Radiogenomics-Based Risk Prediction of Glioblastoma Multiforme with Clinical Relevance

Nimg-79. A Radiomic-Risk Score For Survival Prediction In Glioma: A Large Multi-Institutional Retrospective Validation Study

Exploring the prognostic value and biological pathways of transcriptomics and radiomics patterns in glioblastoma multiforme

Machine Learning Based on a Multiparametric and Multiregional Radiomics Signature Predicts Radiotherapeutic Response in Patients with Glioblastoma

Magnetic resonance imaging (MRI)-based intratumoral and peritumoral radiomics for prognosis prediction in glioma patients

Comparison of MRI Radiomics-Based Machine Learning Survival Models in Predicting Prognosis of Glioblastoma Multiforme

Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant

Optimizing Glioblastoma, IDH-wildtype Treatment Outcomes : A Radiomics and Support Vector Machine -Based Approach to Overall Survival Estimation

Glioblastoma and Radiotherapy: a multi-center AI study for Survival Predictions from MRI (GRASP study)